Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-3. (Cancelled).

4. (Currently Amended) A method of treating ~~or inhibiting~~ hyperproliferative vascular disorders in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formula I having the structure



wherein

R^1, R^2, R^3, R^4, and R^5 are each, independently, hydrogen, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl in which the phenyl moiety is substituted with R^8;

R^6 and R^7 are each, independently, -OH, -OR^9, O-tert-butyldimethylsilyl, O-trialkylsilyl of 1-6 carbon atoms per alkyl moiety, O-triphenylsilyl,



,


,


,



,


, or


;

R^8, R^{10}, R^{11}, and R^{12} are each, independently, hydrogen, -CN, -NO_2, halogen, CF_3, alkyl of 1-6 carbon atoms, acetyl, benzoyl, or alkoxy of 1-6 carbon atoms;

R^9 is acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl in which the phenyl moiety is substituted with R^8;

Y is [[~~O,~~]] S, NH, NMe, or CH_2;

W is halogen, -CN, CF_3, alkyl of 1-6 carbon atoms, haloalkyl of 1-6 carbon atoms, nitroalkyl of 1-6 carbon atoms, cyanoalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-12 carbon atoms, alkoxy of 1-6 carbon atoms, or phenyl mono-, di-, or tri-substituted with R^8;

Z is -NO_2, -NH_2, -NHR^{13}, or -NHCO-Het;

R^{13} is acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, benzoyl in which the phenyl moiety is substituted with R^8, or

R^{13} is an α-amino acid in which the α carboxyl group forms an amide with the nitrogen of Z, wherein if said amino acid is glutamic acid or aspartic acid, the non-α carboxylic acid is an alkyl ester in which the alkyl moiety contains from 1-6 carbon atoms;

Het is pyridyl substituted with R^8, thienyl substituted with R^8, furyl substituted with R^8, oxazolyl substituted with R^8, pyrazinyl substituted with R^8, pyrimidinyl substituted with R^8, or thiazolyl substituted with R^8;

R^{14} is R^8, $-NH_2$, $-CO_2H$, or -NH-acyl of 2-7 carbon atoms; and

n = 0-3;

~~with the proviso that when Z is -NHR^{13} and Y is O, at least one of R^1, R^2, R^3, R^4, and R^5 is hydrogen, or at least one of R^6 and R^7 is OH,~~ or a pharmaceutically acceptable salt thereof.

5. (Currently Amended) A method of treating ~~or inhibiting~~ restenosis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formula I having the structure



wherein

R^1, R^2, R^3, R^4, and R^5 are each, independently, hydrogen, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl in which the phenyl moiety is substituted with R^8;

R^6 and R^7 are each, independently, -OH, $-OR^9$, O-tert-butyldimethylsilyl, O-trialkylsilyl of 1-6 carbon atoms per alkyl moiety, O-triphenylsilyl,








R^8, R^{10}, R^{11}, and R^{12} are each, independently, hydrogen, -CN, -NO_2, halogen, CF_3, alkyl of 1-6 carbon atoms, acetyl, benzoyl, or alkoxy of 1-6 carbon atoms;

R^9 is acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl in which the phenyl moiety is substituted with R^8;

Y is [[~~O~~,]] S, NH, NMe, or CH_2;

W is halogen, -CN, CF_3, alkyl of 1-6 carbon atoms, haloalkyl of 1-6 carbon atoms, nitroalkyl of 1-6 carbon atoms, cyanoalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-12 carbon atoms, alkoxy of 1-6 carbon atoms, or phenyl mono-, di-, or tri-substituted with R^8;

Z is -NO_2, -NH_2, -NHR^{13}, or -NHCO-Het;

R^{13} is acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, benzoyl in which the phenyl moiety is substituted with R^8, or

R^{13} is an α-amino acid in which the α carboxyl group forms an amide with the nitrogen of Z, wherein if said amino acid is glutamic acid or aspartic acid, the non-α carboxylic acid is an alkyl ester in which the alkyl moiety contains from 1-6 carbon atoms;

Het is pyridyl substituted with R^8, thienyl substituted with R^8, furyl substituted with R^8, oxazolyl substituted with R^8, pyrazinyl substituted with R^8, pyrimidinyl substituted with R^8, or thiazolyl substituted with R^8;

R^{14} is R^8, $-NH_2$, $-CO_2H$, or -NH-acyl of 2-7 carbon atoms; and

n = 0-3;

~~with the proviso that when Z is $-NHR^{13}$ and Y is O, at least one of R^1, R^2, R^3, R^4, and R^5 is hydrogen, or at least one of R^6 and R^7 is OH,~~ or a pharmaceutically acceptable salt thereof.

6. (Original) The method according to claim 5, wherein the restenosis results from a vascular angioplasty procedure, vascular reconstructive surgery, or organ or tissue transplantation.

7. (Cancelled)

8. (Cancelled).

9. (New) A method of preventing hyperproliferative vascular disorders following vascular angioplasty procedure, vascular reconstructive surgery, or organ or tissue transplantation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formula I having the structure



I

wherein

R^1, R^2, R^3, R^4, and R^5 are each, independently, hydrogen, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl in which the phenyl moiety is substituted with R^8;

R^6 and R^7 are each, independently, -OH, -OR^9, O-tert-butyldimethylsilyl, O-trialkylsilyl of 1-6 carbon atoms per alkyl moiety, O-triphenylsilyl,


,

,

,


,

, or

;

R^8, R^{10}, R^{11}, and R^{12} are each, independently, hydrogen, -CN, -NO_2, halogen, CF_3, alkyl of 1-6 carbon atoms, acetyl, benzoyl, or alkoxy of 1-6 carbon atoms;

R^9 is acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl in which the phenyl moiety is substituted with R^8;

Y is S, NH, NMe, or CH_2;

W is halogen, -CN, CF_3, alkyl of 1-6 carbon atoms, haloalkyl of 1-6 carbon atoms, nitroalkyl of 1-6 carbon atoms, cyanoalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-12 carbon atoms, alkoxy of 1-6 carbon atoms, or phenyl mono-, di-, or tri-substituted with R^8;

Z is -NO_2, -NH_2, -NHR^{13}, or -NHCO-Het;

R^{13} is acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, benzoyl in which the phenyl moiety is substituted with R^8, or

R^{13} is an α-amino acid in which the α carboxyl group forms an amide with the nitrogen of Z, wherein if said amino acid is glutamic acid or aspartic acid, the non-α carboxylic acid is an alkyl ester in which the alkyl moiety contains from 1-6 carbon atoms;

Het is pyridyl substituted with R^8, thienyl substituted with R^8, furyl substituted with R^8, oxazolyl substituted with R^8, pyrazinyl substituted with R^8, pyrimidinyl substituted with R^8, or thiazolyl substituted with R^8;

R^{14} is R^8, $-NH_2$, $-CO_2H$, or -NH-acyl of 2-7 carbon atoms; and

n = 0-3; or a pharmaceutically acceptable salt thereof.

10. (New) A method of preventing restenosis following vascular angioplasty procedure, vascular reconstructive surgery, or organ or tissue transplantation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formula I having the structure



wherein

R^1, R^2, R^3, R^4, and R^5 are each, independently, hydrogen, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl in which the phenyl moiety is substituted with R^8;

R^6 and R^7 are each, independently, -OH, -OR^9, O-tert-butyldimethylsilyl, O-trialkylsilyl of 1-6 carbon atoms per alkyl moiety, O-triphenylsilyl,



,


,


,



,


, or


;

R^8, R^{10}, R^{11}, and R^{12} are each, independently, hydrogen, -CN, -NO_2, halogen, CF_3, alkyl of 1-6 carbon atoms, acetyl, benzoyl, or alkoxy of 1-6 carbon atoms;

R^9 is acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl in which the phenyl moiety is substituted with R^8;

Y is S, NH, NMe, or CH_2;

W is halogen, -CN, CF_3, alkyl of 1-6 carbon atoms, haloalkyl of 1-6 carbon atoms, nitroalkyl of 1-6 carbon atoms, cyanoalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-12 carbon atoms, alkoxy of 1-6 carbon atoms, or phenyl mono-, di-, or tri-substituted with R^8;

Z is -NO_2, -NH_2, -NHR^{13}, or -NHCO-Het;

R^{13} is acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, benzoyl in which the phenyl moiety is substituted with R^8, or

R^{13} is an α-amino acid in which the α carboxyl group forms an amide with the nitrogen of Z, wherein if said amino acid is glutamic acid or aspartic acid, the non-α carboxylic acid is an alkyl ester in which the alkyl moiety contains from 1-6 carbon atoms;

Het is pyridyl substituted with R^8, thienyl substituted with R^8, furyl substituted with R^8, oxazolyl substituted with R^8, pyrazinyl substituted with R^8, pyrimidinyl substituted with R^8, or thiazolyl substituted with R^8;

R^{14} is R^8, $-NH_2$, $-CO_2H$, or -NH-acyl of 2-7 carbon atoms; and

n = 0-3; or a pharmaceutically acceptable salt thereof.

11. (New) A method of treating hyperproliferative vascular disorders in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound selected from the group consisting of:

N-{5-[(Hepta-*O*-acetyl-β-D-maltosyloxy)-methyl]-2-chloro-phenyl}-L-aspartamide-γ-*tert*- butyl ester or a pharmaceutically acceptable salt thereof;

N-{2-Chloro-5-[(2,2',3,3',4',6,6')-hepta-*O*-acetyl-β-D-maltosyl-oxymethyl]-phenyl}- (9*H*-fluoren-9-ylmethoxycarbonyl)-L-alaninamide or a pharmaceutically acceptable salt thereof;

4-Benzoyl-*N*-{2-chloro-5-[(2,2',3,3',4',6,6'-hepta-*O*-acetyl-β-D-maltosyl)-oxy-methyl]-phenyl}-benzamide or a pharmaceutically acceptable salt thereof;

N-[2-Chloro-5-(β-D-maltosyl-oxymethyl)-phenyl]-acetamide or a pharmaceutically acceptable salt thereof;

N-{5-[6,6'-Di-*O*-(*tert*-butyl-dimethyl-silyl)-β-D-maltosyloxy-methyl]-2-methyl-phenyl}-acetamide or a pharmaceutically acceptable salt thereof;

N-{2-Chloro-5-[6,6'-di-*O*-(*tert*-butyl-dimethyl-silyl)-β-D-maltosyloxy-methyl]-phenyl}-acetamide or a pharmaceutically acceptable salt thereof;

N-{2-Chloro-5-[([6,6'-di-*O*-benzoyl-β-D-maltosyl]oxy)methyl]phenyl}-acetamide or a pharmaceutically acceptable salt thereof;

N-{2-Chloro-5-[([6,6'-di-*O*-benzoyl-2,2',3,3',4'-penta-acetyl-β-D-maltosyl]oxy)-methyl]phenyl}-acetamide or a pharmaceutically acceptable salt thereof;

(4-Chloro-3-nitrophenyl)methyl-4-*O*-[6-*O*-(3-pyridinylcarbonyl)-α-D-glucopyranosyl]-β-D-glucopyranoside-6-(3-pyridinecarboxylate) or a pharmaceutically acceptable salt thereof;

(4-Chloro-3-nitrophenyl)methyl-4-*O*-[6-*O*-(3-pyridinylcarbonyl)-α-D-glucopyranosyl]-β-D-glucopyranoside or a pharmaceutically acceptable salt thereof;

N-[2-Chloro-5-[[(4-*O*-α-D-glucopyranosyl-β-D-glucopyranosyl)oxy]methyl] phenyl]-3-pyridinecarboxamide or a pharmaceutically acceptable salt thereof;

Benzoic acid 6-{4-chloro-3-[(pyridine-3-carbonyl)-amino]-benzyloxy}-4,5-dihydoxy-3- (3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-2- ylmethyl ester or a pharmaceutically acceptable salt thereof;

5-{[6,6'-Bis-*O*-(4-toluenesulfonyl)- β-maltosyl]-oxy-methyl}-2-methyl-1-nitrobenzene or a pharmaceutically acceptable salt thereof;

5-{[2,2',3,3',4'-Penta-*O*-acetyl-6,6'-bis-*O*-(4-toluenesulfonyl)- β-maltosyl]-oxy-methyl}- 2-methyl-1-nitrobenzene or a pharmaceutically acceptable salt thereof;

5-{[6,6'-Dideoxy-6,6'-bis(4-nitro-imidazol-1-yl)- β-maltosyl]-oxy-methyl}-2-methyl-1-nitrobenzene or a pharmaceutically acceptable salt thereof; and

5-{[2,2',3,3',4'-Penta-*O*-acetyl-6,6'-dideoxy-6,6'-bis(4-nitro-imidazol-1-yl)- β-maltosyl]- oxy-methyl}-2-methyl-1-nitrobenzene or a pharmaceutically acceptable salt thereof.

12. (New) A method of treating restenosis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound selected from the group consisting of:

N-{5-[(Hepta-*O*-acetyl-β-D-maltosyloxy)-methyl]-2-chloro-phenyl}-L-aspartamide-γ-*tert*- butyl ester or a pharmaceutically acceptable salt thereof;

N-{2-Chloro-5-[(2,2',3,3',4',6,6')-hepta-*O*-acetyl-β-D-maltosyl-oxymethyl]-phenyl}- (9*H*-fluoren-9-ylmethoxycarbonyl)-L-alaninamide or a pharmaceutically acceptable salt thereof;

4-Benzoyl-*N*-{2-chloro-5-[(2,2',3,3',4',6,6'-hepta-*O*-acetyl-β-D-maltosyl)-oxy-methyl]-phenyl}-benzamide or a pharmaceutically acceptable salt thereof;

N-[2-Chloro-5-(β-D-maltosyl-oxymethyl)-phenyl]-acetamide or a pharmaceutically acceptable salt thereof;

N-{5-[6,6'-Di-*O*-(*tert*-butyl-dimethyl-silyl)-β-D-maltosyloxy-methyl]-2-methyl-phenyl}-acetamide or a pharmaceutically acceptable salt thereof;

N-{2-Chloro-5-[6,6'-di-*O*-(*tert*-butyl-dimethyl-silyl)-β-D-maltosyloxy-methyl]-phenyl}-acetamide or a pharmaceutically acceptable salt thereof;

N-{2-Chloro-5-[([6,6'-di-*O*-benzoyl-β-D-maltosyl]oxy)methyl]phenyl}-acetamide or a pharmaceutically acceptable salt thereof;

N-{2-Chloro-5-[([6,6'-di-*O*-benzoyl-2,2',3,3',4'-penta-acetyl-β-D-maltosyl]oxy)-methyl]phenyl}-acetamide or a pharmaceutically acceptable salt thereof;

(4-Chloro-3-nitrophenyl)methyl-4-*O*-[6-*O*-(3-pyridinylcarbonyl)-α-D-glucopyranosyl]-β-D-glucopyranoside-6-(3-pyridinecarboxylate) or a pharmaceutically acceptable salt thereof;

(4-Chloro-3-nitrophenyl)methyl-4-*O*-[6-*O*-(3-pyridinylcarbonyl)-α-D-glucopyranosyl]-β-D-glucopyranoside or a pharmaceutically acceptable salt thereof;

N-[2-Chloro-5-[[(4-*O*-α-D-glucopyranosyl-β-D-glucopyranosyl)oxy]methyl] phenyl]-3-pyridinecarboxamide or a pharmaceutically acceptable salt thereof;

Benzoic acid 6-{4-chloro-3-[(pyridine-3-carbonyl)-amino]-benzyloxy}-4,5-dihydoxy-3- (3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-2- ylmethyl ester or a pharmaceutically acceptable salt thereof;

5-{[6,6'-Bis-*O*-(4-toluenesulfonyl)- β-maltosyl]-oxy-methyl}-2-methyl-1-nitrobenzene or a pharmaceutically acceptable salt thereof;

5-{[2,2',3,3',4'-Penta-*O*-acetyl-6,6'-bis-*O*-(4-toluenesulfonyl)- β-maltosyl]-oxy-methyl}- 2-methyl-1-nitrobenzene or a pharmaceutically acceptable salt thereof;

5-{[6,6'-Dideoxy-6,6'-bis(4-nitro-imidazol-1-yl)- β-maltosyl]-oxy-methyl}-2-methyl-1-nitrobenzene or a pharmaceutically acceptable salt thereof; and

5-{[2,2',3,3',4'-Penta-*O*-acetyl-6,6'-dideoxy-6,6'-bis(4-nitro-imidazol-1-yl)- β-maltosyl]- oxy-methyl}-2-methyl-1-nitrobenzene or a pharmaceutically acceptable salt thereof.

13. (New) The method according to claim 12, wherein the restenosis results from a vascular angioplasty procedure, vascular reconstructive surgery, or organ or tissue transplantation.

14. (New) A method of preventing hyperproliferative vascular disorders following vascular angioplasty procedure, vascular reconstructive surgery, or organ or tissue transplantation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound selected from the group consisting of:

N-{5-[(Hepta-*O*-acetyl-β-D-maltosyloxy)-methyl]-2-chloro-phenyl}-L-aspartamide-γ-*tert*- butyl ester or a pharmaceutically acceptable salt thereof;

N-{2-Chloro-5-[(2,2',3,3',4',6,6')-hepta-*O*-acetyl-β-D-maltosyl-oxymethyl]-phenyl}- (9*H*-fluoren-9-ylmethoxycarbonyl)-L-alaninamide or a pharmaceutically acceptable salt thereof;

4-Benzoyl-*N*-{2-chloro-5-[(2,2',3,3',4',6,6'-hepta-*O*-acetyl-β-D-maltosyl)-oxy-methyl]-phenyl}-benzamide or a pharmaceutically acceptable salt thereof;

N-[2-Chloro-5-(β-D-maltosyl-oxymethyl)-phenyl]-acetamide or a pharmaceutically acceptable salt thereof;

N-{5-[6,6'-Di-*O*-(*tert*-butyl-dimethyl-silyl)-β-D-maltosyloxy-methyl]-2-methyl-phenyl}-acetamide or a pharmaceutically acceptable salt thereof;

N-{2-Chloro-5-[6,6'-di-*O*-(*tert*-butyl-dimethyl-silyl)-β-D-maltosyloxy-methyl]-phenyl}-acetamide or a pharmaceutically acceptable salt thereof;

N-{2-Chloro-5-[([6,6'-di-*O*-benzoyl-β-D-maltosyl]oxy)methyl]phenyl}-acetamide or a pharmaceutically acceptable salt thereof;

N-{2-Chloro-5-[([6,6'-di-*O*-benzoyl-2,2',3,3',4'-penta-acetyl-β-D-maltosyl]oxy)-methyl]phenyl}-acetamide or a pharmaceutically acceptable salt thereof;

(4-Chloro-3-nitrophenyl)methyl-4-*O*-[6-*O*-(3-pyridinylcarbonyl)-α-D-glucopyranosyl]-β-D-glucopyranoside-6-(3-pyridinecarboxylate) or a pharmaceutically acceptable salt thereof;

(4-Chloro-3-nitrophenyl)methyl-4-*O*-[6-*O*-(3-pyridinylcarbonyl)-α-D-glucopyranosyl]-β-D-glucopyranoside or a pharmaceutically acceptable salt thereof;

N-[2-Chloro-5-[[(4-*O*-α-D-glucopyranosyl-β-D-glucopyranosyl)oxy]methyl] phenyl]-3-pyridinecarboxamide or a pharmaceutically acceptable salt thereof;

Benzoic acid 6-{4-chloro-3-[(pyridine-3-carbonyl)-amino]-benzyloxy}-4,5-dihydoxy-3- (3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-2- ylmethyl ester or a pharmaceutically acceptable salt thereof;

5-{[6,6'-Bis-*O*-(4-toluenesulfonyl)- β-maltosyl]-oxy-methyl}-2-methyl-1-nitrobenzene or a pharmaceutically acceptable salt thereof;

5-{[2,2',3,3',4'-Penta-*O*-acetyl-6,6'-bis-*O*-(4-toluenesulfonyl)- β-maltosyl]-oxy-methyl}- 2-methyl-1-nitrobenzene or a pharmaceutically acceptable salt thereof;

5-{[6,6'-Dideoxy-6,6'-bis(4-nitro-imidazol-1-yl)- β-maltosyl]-oxy-methyl}-2-methyl-1-nitrobenzene or a pharmaceutically acceptable salt thereof; and

5-{[2,2',3,3',4'-Penta-*O*-acetyl-6,6'-dideoxy-6,6'-bis(4-nitro-imidazol-1-yl)- β-maltosyl]- oxy-methyl}-2-methyl-1-nitrobenzene or a pharmaceutically acceptable salt thereof.

15. (New) A method of preventing restenosis following vascular angioplasty procedure, vascular reconstructive surgery, or organ or tissue transplantation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound selected from the group consisting of:

N-{5-[(Hepta-*O*-acetyl-β-D-maltosyloxy)-methyl]-2-chloro-phenyl}-L-aspartamide-γ-*tert*- butyl ester or a pharmaceutically acceptable salt thereof;

N-{2-Chloro-5-[(2,2',3,3',4',6,6')-hepta-*O*-acetyl-β-D-maltosyl-oxymethyl]-phenyl}- (9*H*-fluoren-9-ylmethoxycarbonyl)-L-alaninamide or a pharmaceutically acceptable salt thereof;

4-Benzoyl-*N*-{2-chloro-5-[(2,2',3,3',4',6,6'-hepta-*O*-acetyl-β-D-maltosyl)-oxy-methyl]-phenyl}-benzamide or a pharmaceutically acceptable salt thereof;

N-[2-Chloro-5-(β-D-maltosyl-oxymethyl)-phenyl]-acetamide or a pharmaceutically acceptable salt thereof;

N-{5-[6,6'-Di-*O*-(*tert*-butyl-dimethyl-silyl)-β-D-maltosyloxy-methyl]-2-methyl-phenyl}-acetamide or a pharmaceutically acceptable salt thereof;

N-{2-Chloro-5-[6,6'-di-*O*-(*tert*-butyl-dimethyl-silyl)-β-D-maltosyloxy-methyl]-phenyl}-acetamide or a pharmaceutically acceptable salt thereof;

N-{2-Chloro-5-[([6,6'-di-*O*-benzoyl-β-D-maltosyl]oxy)methyl]phenyl}-acetamide or a pharmaceutically acceptable salt thereof;

N-{2-Chloro-5-[([6,6'-di-*O*-benzoyl-2,2',3,3',4'-penta-acetyl-β-D-maltosyl]oxy)-methyl]phenyl}-acetamide or a pharmaceutically acceptable salt thereof;

(4-Chloro-3-nitrophenyl)methyl-4-*O*-[6-*O*-(3-pyridinylcarbonyl)-α-D-glucopyranosyl]-β-D-glucopyranoside-6-(3-pyridinecarboxylate) or a pharmaceutically acceptable salt thereof;

(4-Chloro-3-nitrophenyl)methyl-4-*O*-[6-*O*-(3-pyridinylcarbonyl)-α-D-glucopyranosyl]-β-D-glucopyranoside or a pharmaceutically acceptable salt thereof;

N-[2-Chloro-5-[[(4-*O*-α-D-glucopyranosyl-β-D-glucopyranosyl)oxy]methyl] phenyl]-3-pyridinecarboxamide or a pharmaceutically acceptable salt thereof;

Benzoic acid 6-{4-chloro-3-[(pyridine-3-carbonyl)-amino]-benzyloxy}-4,5-dihydoxy-3- (3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-2- ylmethyl ester or a pharmaceutically acceptable salt thereof;

5-{[6,6'-Bis-*O*-(4-toluenesulfonyl)- β-maltosyl]-oxy-methyl}-2-methyl-1-nitrobenzene or a pharmaceutically acceptable salt thereof;

5-{[2,2',3,3',4'-Penta-*O*-acetyl-6,6'-bis-*O*-(4-toluenesulfonyl)- β-maltosyl]-oxy-methyl}- 2-methyl-1-nitrobenzene or a pharmaceutically acceptable salt thereof;

5-{[6,6'-Dideoxy-6,6'-bis(4-nitro-imidazol-1-yl)- β-maltosyl]-oxy-methyl}-2-methyl-1-nitrobenzene or a pharmaceutically acceptable salt thereof; and

5-{[2,2',3,3',4'-Penta-*O*-acetyl-6,6'-dideoxy-6,6'-bis(4-nitro-imidazol-1-yl)- β-maltosyl]- oxy-methyl}-2-methyl-1-nitrobenzene or a pharmaceutically acceptable salt thereof.